Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.56 |
| ▸ | NCF1 | P14598 | 5/20 | 0.56 |
| ▸ | HTR1A | P08908 | 4/20 | 0.56 |
| ▸ | HTR7 | P34969 | 3/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR5A | P47898 | 2/20 | 0.56 |
| ▸ | HTR1D | P28221 | 2/20 | 0.56 |
| ▸ | HTR1B | P28222 | 2/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.56 |
| ▸ | HTR3B | O95264 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | HTR3A | P46098 | 1/20 | 0.56 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.56 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2711261 | 0.84 | KDM4E (0.74) | HTR6NCF1HTR1AHTR7HTR2A | |
| SCHEMBL4178083 | 0.80 | KDM4E (0.49) | NCF1HTR1AHTR1DHTR1BTSHR | |
| SCHEMBL27656377 | 0.79 | NCF1 (0.55) | HTR6NCF1HTR1AHTR7HTR2A | |
| SCHEMBL428165 | 0.79 | NCF1 (0.69) | HTR6NCF1HTR1AHTR7HTR2A | |
| SCHEMBL5369315 | 0.76 | NCF1 (0.53) | HTR6NCF1HTR1AHTR7HTR2A | |
| SCHEMBL429723 | 0.76 | NCF1 (0.51) | HTR6NCF1HTR1AHTR7HTR2A | |
| SCHEMBL425929 | 0.76 | ADRB2 (0.71) | HTR6NCF1HTR1AHTR7HTR2A | |
| SCHEMBL430944 | 0.76 | NCF1 (0.51) | HTR6NCF1HTR1AHTR7HTR2A | |
| SCHEMBL430602 | 0.76 | NCF1 (0.51) | HTR6NCF1HTR1AHTR7HTR2A | |
| SCHEMBL4176462 | 0.75 | NCF1 (0.72) | HTR6NCF1HTR1AHTR7HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED | 2009-03-19 | — | — | US | disclosed |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1562917-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046124-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | XDH, CYP4X1, PDHX | HTR6 101/4885NCF1 3910/4885HTR1A 47/4885 |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | XDH, CYP4X1, PDHX | HTR6 406/4885NCF1 3681/4885HTR1A 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.